Carna Biosciences, Inc. (4572.T)
JPY 280.0
(-1.41%)
JPY 280.0
(-1.41%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 2.56 Billion JPY | 3.32% |
| 2022 | 2.48 Billion JPY | 2.98% |
| 2021 | 2.41 Billion JPY | 20.77% |
| 2020 | 1.99 Billion JPY | -1.18% |
| 2019 | 2.02 Billion JPY | 22.66% |
| 2018 | 1.64 Billion JPY | 45.36% |
| 2017 | 1.13 Billion JPY | 15.59% |
| 2016 | 981.14 Million JPY | 18.66% |
| 2015 | 826.82 Million JPY | -18.44% |
| 2014 | 1.01 Billion JPY | 20.68% |
| 2013 | 840.05 Million JPY | 10.78% |
| 2012 | 758.3 Million JPY | -3.25% |
| 2011 | 783.74 Million JPY | 2.03% |
| 2010 | 768.15 Million JPY | -5.81% |
| 2009 | 815.52 Million JPY | 21.21% |
| 2008 | 672.84 Million JPY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 777.57 Million JPY | 41.26% |
| 2024 Q1 | 550.43 Million JPY | -29.26% |
| 2023 Q1 | 684.12 Million JPY | -9.92% |
| 2023 Q2 | 597.45 Million JPY | -12.67% |
| 2023 Q4 | 778.16 Million JPY | 53.24% |
| 2023 FY | 2.56 Billion JPY | 3.32% |
| 2023 Q3 | 507.82 Million JPY | -15.0% |
| 2022 Q2 | 557.45 Million JPY | 9.08% |
| 2022 FY | 2.48 Billion JPY | 2.98% |
| 2022 Q4 | 759.44 Million JPY | 15.57% |
| 2022 Q1 | 511.03 Million JPY | -27.36% |
| 2022 Q3 | 657.15 Million JPY | 17.89% |
| 2021 Q4 | 703.54 Million JPY | 23.12% |
| 2021 FY | 2.41 Billion JPY | 20.77% |
| 2021 Q1 | 483.81 Million JPY | -27.54% |
| 2021 Q2 | 654.49 Million JPY | 35.28% |
| 2021 Q3 | 571.42 Million JPY | -12.69% |
| 2020 Q4 | 667.68 Million JPY | 46.34% |
| 2020 Q3 | 456.25 Million JPY | 10.56% |
| 2020 Q2 | 412.66 Million JPY | -10.62% |
| 2020 Q1 | 461.66 Million JPY | -30.79% |
| 2020 FY | 1.99 Billion JPY | -1.18% |
| 2019 FY | 2.02 Billion JPY | 22.66% |
| 2019 Q4 | 667.06 Million JPY | 53.13% |
| 2019 Q2 | 560.19 Million JPY | 55.97% |
| 2019 Q1 | 359.16 Million JPY | -24.83% |
| 2019 Q3 | 435.63 Million JPY | -22.24% |
| 2018 Q2 | 390.82 Million JPY | 16.77% |
| 2018 Q3 | 445.16 Million JPY | 13.9% |
| 2018 Q1 | 334.7 Million JPY | -1.89% |
| 2018 FY | 1.64 Billion JPY | 45.36% |
| 2018 Q4 | 477.81 Million JPY | 7.33% |
| 2017 Q3 | 286.86 Million JPY | 9.79% |
| 2017 Q2 | 261.27 Million JPY | 6.74% |
| 2017 Q1 | 244.76 Million JPY | -4.23% |
| 2017 FY | 1.13 Billion JPY | 15.59% |
| 2017 Q4 | 341.16 Million JPY | 18.93% |
| 2016 Q3 | 223.88 Million JPY | -6.18% |
| 2016 Q1 | 263.05 Million JPY | -12.25% |
| 2016 FY | 981.14 Million JPY | 18.66% |
| 2016 Q4 | 255.57 Million JPY | 14.16% |
| 2016 Q2 | 238.63 Million JPY | -9.29% |
| 2015 FY | 826.82 Million JPY | -18.44% |
| 2015 Q3 | 190.48 Million JPY | 14.7% |
| 2015 Q4 | 299.77 Million JPY | 57.37% |
| 2015 Q2 | 166.07 Million JPY | -2.59% |
| 2015 Q1 | 170.48 Million JPY | -45.05% |
| 2014 Q2 | 253.44 Million JPY | 13.95% |
| 2014 FY | 1.01 Billion JPY | 20.68% |
| 2014 Q1 | 222.41 Million JPY | -4.48% |
| 2014 Q3 | 227.63 Million JPY | -10.18% |
| 2014 Q4 | 310.25 Million JPY | 36.29% |
| 2013 Q1 | 189.7 Million JPY | 4.26% |
| 2013 Q4 | 232.85 Million JPY | 13.75% |
| 2013 Q3 | 204.7 Million JPY | -3.8% |
| 2013 Q2 | 212.78 Million JPY | 12.17% |
| 2013 FY | 840.05 Million JPY | 10.78% |
| 2012 Q3 | 189.01 Million JPY | -5.59% |
| 2012 Q4 | 181.95 Million JPY | -3.74% |
| 2012 FY | 758.3 Million JPY | -3.25% |
| 2012 Q2 | 200.21 Million JPY | 7.0% |
| 2012 Q1 | 187.12 Million JPY | -2.99% |
| 2011 Q1 | 180.43 Million JPY | -0.91% |
| 2011 Q3 | 184.67 Million JPY | -18.2% |
| 2011 Q4 | 192.88 Million JPY | 4.45% |
| 2011 FY | 783.74 Million JPY | 2.03% |
| 2011 Q2 | 225.75 Million JPY | 25.12% |
| 2010 FY | 768.15 Million JPY | -5.81% |
| 2010 Q1 | 194.15 Million JPY | -17.21% |
| 2010 Q3 | 183.3 Million JPY | -12.13% |
| 2010 Q4 | 182.09 Million JPY | -0.66% |
| 2010 Q2 | 208.6 Million JPY | 7.44% |
| 2009 FY | 815.52 Million JPY | 21.21% |
| 2009 Q1 | 194.11 Million JPY | 0.0% |
| 2009 Q2 | 193.03 Million JPY | -0.56% |
| 2009 Q3 | 193.85 Million JPY | 0.42% |
| 2009 Q4 | 234.52 Million JPY | 20.98% |
| 2008 FY | 672.84 Million JPY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 1.28 Billion JPY | -99.893% |
| PRISM BioLab Co.,LTD | 576.81 Million JPY | -345.13% |
| GNI Group Ltd. | 9.32 Billion JPY | 72.458% |
| Linical Co., Ltd. | 2.7 Billion JPY | 5.087% |
| Trans Genic Inc. | 2.15 Billion JPY | -18.879% |
| MEDINET Co., Ltd. | 1.49 Billion JPY | -72.186% |
| Soiken Holdings Inc. | 3.07 Billion JPY | 16.395% |
| Cytori Cell Research Institute, Inc. | 1.85 Billion JPY | -38.266% |
| AnGes, Inc. | 8.9 Billion JPY | 71.158% |
| OncoTherapy Science, Inc. | 943.08 Million JPY | -172.254% |
| Nxera Pharma Co., Ltd. | 19.19 Billion JPY | 86.62% |
| Immuno-Biological Laboratories Co., Ltd. | 412.99 Million JPY | -521.704% |
| NanoCarrier Co., Ltd. | 975.37 Million JPY | -163.241% |
| CanBas Co., Ltd. | 278 Million JPY | -823.588% |
| D. Western Therapeutics Institute, Inc. | 1.14 Billion JPY | -124.923% |
| RaQualia Pharma Inc. | 1.81 Billion JPY | -41.235% |
| Chiome Bioscience Inc. | 1.6 Billion JPY | -60.097% |
| Kidswell Bio Corporation | 2.37 Billion JPY | -8.151% |
| PeptiDream Inc. | 9.68 Billion JPY | 73.495% |
| Oncolys BioPharma Inc. | 1.96 Billion JPY | -30.959% |
| Ribomic Inc. | 1.1 Billion JPY | -132.214% |
| SanBio Company Limited | 4.53 Billion JPY | 43.433% |
| Healios K.K. | 3.48 Billion JPY | 26.367% |
| BrightPath Biotherapeutics Co., Ltd. | 1.15 Billion JPY | -122.351% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 1.33 Billion JPY | -92.405% |
| Delta-Fly Pharma, Inc. | 1.4 Billion JPY | -82.946% |
| StemRIM | 2.07 Billion JPY | -23.679% |
| CellSource Co., Ltd. | 1.96 Billion JPY | -30.765% |
| FunPep Company Limited | 313.82 Million JPY | -718.165% |
| Kringle Pharma, Inc. | 958.01 Million JPY | -168.011% |
| Stella Pharma Corporation | 963.98 Million JPY | -166.35% |
| TMS Co., Ltd. | 943.25 Million JPY | -172.204% |
| Noile-Immune Biotech Inc. | 1.08 Billion JPY | -135.568% |
| Cuorips Inc. | 598.11 Million JPY | -329.275% |
| K Pharma,Inc. | 543.94 Million JPY | -372.031% |
| Takara Bio Inc. | 23.9 Billion JPY | 89.259% |
| ReproCELL Incorporated | 1.51 Billion JPY | -69.587% |
| PhoenixBio Co., Ltd. | 1.18 Billion JPY | -116.858% |
| StemCell Institute Inc. | 1.16 Billion JPY | -120.938% |
| Japan Tissue Engineering Co., Ltd. | 1.52 Billion JPY | -68.667% |
| CellSeed Inc. | 804.93 Million JPY | -218.981% |